{"organizations": [], "uuid": "d9301bff02c566c857741faa46136a3dcb97c63f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180430.html", "section_title": "Archive News &amp; Video for Monday, 30 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-curetis-cash-and-cash-equivalents/brief-curetis-cash-and-cash-equivalents-at-end-dec-eur-16-3-million-idUSASO00040P", "country": "US", "domain_rank": 408, "title": "BRIEF-Curetis: Cash And Cash Equivalents At End-Dec. EUR 16.3 Million", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.907, "site_type": "news", "published": "2018-04-30T13:16:00.000+03:00", "replies_count": 0, "uuid": "d9301bff02c566c857741faa46136a3dcb97c63f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-curetis-cash-and-cash-equivalents/brief-curetis-cash-and-cash-equivalents-at-end-dec-eur-16-3-million-idUSASO00040P", "ord_in_thread": 0, "title": "BRIEF-Curetis: Cash And Cash Equivalents At End-Dec. EUR 16.3 Million", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "u.s", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "u.s. fda", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 30 (Reuters) - CURETIS NV:\n* CURETIS PUBLISHES FULL-YEAR 2017 FINANCIAL RESULTS AND UPDATED GUIDANCE FOR 2018\n* RECEIVED U.S. FDA CLEARANCE FOR UNYVERO SYSTEM AND UNYVERO LRT CARTRIDGE; COMMERCIAL U.S. ROLL-OUT INITIATED\n* FY REVENUES: EUR 1.2 MILLION (EUR 1.3 MILLION IN 2016) * OPERATING LOSS IN 2017 TOTALED EUR -18.6 MILLION, COMPARED WITH EUR -15.2 MILLION IN 2016\n* FY NET LOSS: EUR -19.3 MILLION (EUR -15.2 MILLION IN 2016)\n* CASH AND CASH EQUIVALENTS AT END DEC EUR 16.3 MILLION VERSUS EUR 22.8MLN YEAR AGO\n* UNYVERO SYSTEM AND UNYVERO LRT APPLICATION CARTRIDGE COMMERCIAL LAUNCH IN U.S. IN Q2-2018\n* SALES OF LRT APPLICATION CARTRIDGE ARE ANTICIPATED TO RAMP UP BY END OF 2018\n* EXPECTS TO EXPERIENCE POSITIVE REVENUE EFFECTS TOWARDS END OF 2018 AND GOING FORWARD.\n* EXPECTS TO INITIATE SITES FOR PROSPECTIVE PATIENT SAMPLE ENROLLMENT INTO ITS SECOND U.S. FDA CLINICAL TRIAL FOR UNYVERO IJI INVASIVE JOINT INFECTION APPLICATION CARTRIDGE BEGINNING IN H2-2018\n* EXPECTS TO COMPLETE UNYVERO IJI INVASIVE JOINT INFECTION APPLICATION CARTRIDGE TRIAL IN 2019\n* AIMS TO INITIATE PROSPECTIVE CLINICAL TRIALS IN CHINA IN SECOND HALF OF 2018.\n* OBJECTIVE IS TO COMPLETE FIRST TRIALS IN 2019, WITH SUBSEQUENT CFDA SUBMISSION AND APPROVALS\n* EXPECTS TO RECEIVE CE-IVD MARKING FOR UNYVERO A30 RQ ANALYZER AS WELL AS FIRST A30 RQ APPLICATION CARTRIDGES DURING COURSE OF 2019.\n* EXPECTS FIRST RESULTS AND INITIAL PRODUCT LAUNCHES FROM MEMORANDUM OF UNDERSTANDING (MOU) SIGNED WITH MGI (A BGI GROUP COMPANY, CHINA) IN 2018 AND 2019 TIMEFRAME\n* AIMS TO AT LEAST DOUBLE ITS REVENUE YEAR-OVER-YEAR IN 2018.\n* EXPECTS NET CASH-BURN FROM OPERATING AND INVESTMENT ACTIVITIES FOR 2018 TO BE AROUND 30 MILLION EUR\n* ALSO EXPECTS TO FURTHER GROW ITS EMPLOYEE BASE AT ITS VARIOUS INTERNATIONAL SITES AND OPERATIONS IN COMING YEARS. Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-30T13:16:00.000+03:00", "crawled": "2018-05-01T20:18:58.000+03:00", "highlightTitle": ""}